Total Payments
$418,426
2024 Payments
$65,153
Companies
27
Transactions
338
Medicare Patients
322
Medicare Billing
$100,325
Payment Breakdown by Category
Consulting$204,594 (48.9%)
Other$136,469 (32.6%)
Travel$65,439 (15.6%)
Food & Beverage$7,843 (1.9%)
Research$3,750 (0.9%)
Gifts$243.45 (0.1%)
Education$87.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $204,594 | 66 | 48.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,481 | 14 | 17.1% |
| Travel and Lodging | $65,439 | 98 | 15.6% |
| Honoraria | $64,988 | 22 | 15.5% |
| Food and Beverage | $7,843 | 129 | 1.9% |
| Unspecified | $3,750 | 2 | 0.9% |
| Gift | $243.45 | 5 | 0.1% |
| Education | $87.00 | 2 | 0.0% |
Payments by Type
General
$414,676
336 transactions
Research
$3,750
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| H. Lundbeck A S | $85,210 | 41 | $0 (2024) |
| Otsuka Pharmaceutical Co., Ltd. | $69,972 | 46 | $0 (2024) |
| Alkermes, Inc. | $48,135 | 61 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $26,314 | 16 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $26,290 | 19 | $0 (2019) |
| Janssen Research & Development, LLC | $22,554 | 19 | $0 (2021) |
| Merck Sharp & Dohme LLC | $22,029 | 28 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $21,375 | 21 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $13,651 | 14 | $0 (2024) |
| Sage Therapeutics, Inc. | $11,837 | 13 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,153 | 49 | Otsuka Pharmaceutical Co., Ltd. ($33,916) |
| 2023 | $75,063 | 68 | Otsuka Pharmaceutical Co., Ltd. ($27,765) |
| 2022 | $38,599 | 20 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($8,694) |
| 2021 | $37,593 | 15 | H. Lundbeck A S ($18,898) |
| 2020 | $22,783 | 14 | Merck Sharp & Dohme Corporation ($5,625) |
| 2019 | $85,738 | 62 | H. Lundbeck A S ($23,134) |
| 2018 | $56,158 | 63 | Alkermes, Inc. ($16,572) |
| 2017 | $37,339 | 47 | Alkermes, Inc. ($23,907) |
All Payment Transactions
338 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| 12/05/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $362.50 | General |
| 10/31/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $61.72 | General |
| Category: PSYCHIATRY | ||||||
| 10/14/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,625.00 | General |
| 08/20/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 07/31/2024 | Otsuka Pharmaceutical Co., Ltd. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,210.00 | General |
| Category: PSYCHIATRY | ||||||
| 05/31/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $4,725.00 | General |
| 05/31/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $2,725.00 | General |
| 05/31/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | Cash or cash equivalent | $403.97 | General |
| 05/31/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | Cash or cash equivalent | $118.05 | General |
| 05/31/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | Cash or cash equivalent | $52.00 | General |
| 05/31/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | Cash or cash equivalent | $46.00 | General |
| 05/31/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | Cash or cash equivalent | $7.50 | General |
| 05/31/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | Cash or cash equivalent | $7.50 | General |
| 05/02/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | In-kind items and services | $533.60 | General |
| 05/02/2024 | Janssen Scientific Affairs, LLC | — | Travel and Lodging | In-kind items and services | $312.17 | General |
| 05/02/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $55.61 | General |
| 05/02/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $28.05 | General |
| 04/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $7,236.00 | General |
| Category: PSYCHIATRY | ||||||
| 03/26/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $420.00 | General |
| 03/16/2024 | H. Lundbeck A S | REXULTI (Drug), BRINTELLIX, ESCITALOPRAM | Honoraria | Cash or cash equivalent | $3,300.00 | General |
| Category: PSYCHIATRY | ||||||
| 03/13/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $46.00 | General |
| Category: PSYCHIATRY | ||||||
| 03/13/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $30.99 | General |
| Category: PSYCHIATRY | ||||||
| 03/13/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: PSYCHIATRY | ||||||
| 03/13/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-042 | ACADIA Pharmaceuticals Inc | $3,750 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 80 | 375 | $79,441 | $28,268 |
| 2022 | 3 | 82 | 355 | $66,551 | $26,834 |
| 2021 | 3 | 75 | 357 | $64,161 | $28,439 |
| 2020 | 4 | 85 | 250 | $46,313 | $16,783 |
Total Patients
322
Total Services
1,337
Medicare Billing
$100,325
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 236 | $52,647 | $16,836 | 32.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 38 | 124 | $20,725 | $9,226 | 44.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 13 | 15 | $6,069 | $2,207 | 36.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 187 | $40,361 | $13,834 | 34.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 157 | $23,200 | $11,686 | 50.4% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 11 | 11 | $2,990 | $1,314 | 44.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 44 | 166 | $24,260 | $13,393 | 55.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 17 | 177 | $37,246 | $13,110 | 35.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 14 | 14 | $2,655 | $1,936 | 72.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 40 | 125 | $19,905 | $8,664 | 43.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 73 | $15,089 | $4,528 | 30.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 15 | 31 | $4,063 | $1,800 | 44.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 15 | 21 | $7,256 | $1,792 | 24.7% |
About Dr. Michael Thase, MD
Dr. Michael Thase, MD is a Psychiatry healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982670279.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Thase, MD has received a total of $418,426 in payments from pharmaceutical and medical device companies, with $65,153 received in 2024. These payments were reported across 338 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($204,594).
As a Medicare-enrolled provider, Thase has provided services to 322 Medicare beneficiaries, totaling 1,337 services with total Medicare billing of $100,325. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychoanalyst, Specialist
- Location Philadelphia, PA
- Active Since 02/27/2006
- Last Updated 10/10/2012
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1982670279
Products in Payments
- REXULTI (Drug) $169,827
- SPRAVATO (Drug) $25,990
- TRINTELLIX (Drug) $21,290
- PRISTIQ (Drug) $8,933
- NUPLAZID (Drug) $4,150
- SUNOSI (Drug) $3,734
- Rykindo (Drug) $3,655
- BRINTELLIX (Drug) $3,375
- MK-1942 (Drug) $2,250
- Aristada 441 mg (Drug) $1,004
- CAPLYTA (Drug) $103.89
- Vivitrol 380 mg (Drug) $42.00
- VRAYLAR (Drug) $24.08
- Auvelity (Drug) $20.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Philadelphia
Daniel Weintraub, Md, MD
Psychiatry — Payments: $614,211
Psychiatry $614,211
Dr. Karl Doghramji, Md, MD
Psychiatry — Payments: $130,409
Psychiatry $130,409
Richard Jaffe, Md, MD
Psychiatry — Payments: $126,747
Psychiatry $126,747
Kyle Kampman, Md, MD
Psychiatry — Payments: $118,739
Psychiatry $118,739
Ramesh Eluri, M.d, M.D
Psychiatry — Payments: $88,982
Psychiatry $88,982
John Lauriello, Md, MD
Psychiatry — Payments: $75,274
Psychiatry $75,274